Kiniciti is a new Welsh, Carson, Anderson & Stowe platform established to partner with companies that have the potential to transform the cell and gene therapy ecosystem and deliver the promise of these therapies to impact patients’ lives. Bringing novel treatments to the patients who need them most — in an economically viable way — is too often crippled by persistent bottlenecks, constraints and inefficiencies in the development, manufacturing and delivery of those innovations. At Kiniciti, our imperative is to make the promise of breakthrough CGT therapies a reality, so that future treatments reach patients as quickly and cost-efficiently as possible. There can’t be a tradeoff between scientific advancements and patients’ access to life-changing therapies; both must be addressed simultaneously. Kiniciti is focused on investing in opportunities with the potential to leverage technology and capabilities that can help drive transformational change and ensure the promise of CGT therapeutics is delivered to patients in need. So we’re ready and able to pursue partnerships in: • Cell sources and other enabling quality- controlled starting and raw materials • Enabling technology platforms (including cell-programming and gene- editing innovations) • Key tools, services and enablers for process development and scale-up • Innovations and solutions from source-to-patient delivery • Other solutions designed to fulfill the promise of breakthrough treatments while concurrently reducing costs to ensure affordable access for patients In forming Kiniciti, Welsh, Carson, Anderson & Stowe (WCAS) hand-selected leading life sciences executives and committed a minimum of $250M to support companies primed to transform healthcare through their CGT offerings. While control-stake investments are part of our WCAS pedigree and our preference when appropriate, Kiniciti has a flexible remit to ensure that we invest in the right companies, with the right technology, at the right time.